Merck Gains FDA Label Update for WINREVAIR in PAH
RAHWAY, N.J. — September 22, 2026 Merck announced that the U.S. Food and Drug Administration (FDA) has approved an...
pulmonary arterial hypertension
Advertisement
Insmed Presents New ARIKAYCE Data From Phase 3b ENCORE
Bridgewater, New Jersey, USA, September 3, 2026 Insmed Incorporated announced that five abstracts from its respiratory portfolio have been...
Ingenia Therapeutics Goes Public to Accelerate Vascular Therapies
BOSTON, Massachusetts, and Seoul, South Korea — August 18, 2026 Ingenia Therapeutics announced that its shares have begun trading...
CalciMedica Advances Auxora and CM5480 in Pulmonary Hypertension
LA JOLLA, Calif., August 11, 2026 CalciMedica, Inc. reported its second-quarter 2026 financial results and provided updates across its...
United Therapeutics Reports Phase 3 Ralinepag Results in The Lancet
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., July 29, 2026 United Therapeutics Corporation announced that the complete results...
Advertisements
Gossamer Bio Reacquires Global Rights to Seralutinib
San Diego, California, July 27, 2026 Gossamer Bio, Inc. announced a series of significant regulatory, strategic, and financial milestones...
Inhibikase Gains FDA Orphan Drug Status for IKT-001 in PAH
WILMINGTON, Del., July 23, 2026 Inhibikase Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
Corsair Pharma Showcases Positive Phase 1 TRX-248 Data at PHA 2026
NEWARK, Calif., June 8, 2026 Corsair Pharma, Inc. announced three presentations showcasing positive Phase 1 clinical data for its...
Tiakis Advances Tiprelestat into Phase II for Pulmonary Hypertension
Kiel, Germany, December 2, 2025 — Tiakis Biotech has announced that it has successfully completed the required preclinical data...
Advertisement
